NATIONAL COMMUNITY PHARMACISTS ASSOCIATION for NATIONAL COMMUNITY PHARMACISTS ASSOCIATION
What was lobbied
9 issue areas, each in the filer's own words, with who lobbied on it and where.
Insurance INS
Rutledge v. Pharmaceutical Care Management Association; pet. for cert. granted, No.18-540 (U.S.)
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANNE CASSITY | — |
| PHILLIP ADAM HARBISON | — |
| RONNA HAUSER | — |
| KARRY LA VIOLETTE | — |
| KALA SHANKLE | — |
| REEMA TANEJA | — |
Animals ANI
H.R. 1607, Fairness to Pet Owners Act of 2019
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANNE CASSITY | — |
| PHILLIP ADAM HARBISON | — |
| RONNA HAUSER | — |
| KARRY LA VIOLETTE | — |
| KALA SHANKLE | — |
| REEMA TANEJA | — |
Defense DEF
Tricare pharmacy issues
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANNE CASSITY | — |
| PHILLIP ADAM HARBISON | — |
| RONNA HAUSER | — |
| KARRY LA VIOLETTE | — |
| KALA SHANKLE | — |
| REEMA TANEJA | — |
Alcohol and Drug Abuse ALC
H.R. 127, CARERS Act of 2019; H.R. 171, the Legitimate Use of Medical Marihuana Act; H.R. 1845, ALERT Act of 2019; S. 516, Prescription Drug Monitoring Act of 2019; H.R. 1588, Ending Federal Marijuana Prohibition Act of 2019; Implementation of pharmacy provisions of Public Law No: 115-271; Implementation of Hemp provisions of Public Law No: 115-334; H.R. 4810, the Opioid Prescription Verification Act of 2019; S. 3070, the Preventing Pill Mills Through Data Sharing Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANNE CASSITY | — |
| PHILLIP ADAM HARBISON | — |
| RONNA HAUSER | — |
| KARRY LA VIOLETTE | — |
| KALA SHANKLE | — |
| REEMA TANEJA | — |
Taxation/Internal Revenue Code TAX
S. 172/H.R. 1398, Health Insurance Tax Relief Act of 2019; S. 215/H.R. 218, Death Tax Repeal Act of 2019; S. 1089/ H.R. 1922, Restoring Access to Medication Act of 2019; Final rule on Qualified Business Income Deduction; S. 1149/H.R. 216, the Main Street Tax Certainty Act of 2019
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANNE CASSITY | — |
| PHILLIP ADAM HARBISON | — |
| RONNA HAUSER | — |
| KARRY LA VIOLETTE | — |
| KALA SHANKLE | — |
| REEMA TANEJA | — |
Health Issues HCR
S. 474, Stop the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act; H.R. 447 / S. 97, Affordable and Safe Prescription Drug Importation Act; S. 61 / H.R. 478, Safe and Affordable Drugs from Canada Act of 2019; S. 102 / H.R. 465, Prescription Drug Price Relief Act of 2019; H.R.1478, Affordable Insulin Act of 2019; S. 3, Keeping Health Insurance Affordable Act of 2019; H.R 965 / S. 340, CREATES Act of 2019; H.R. 1332, Fair Care Act of 2019; S. 637, CURE High Drug Prices Act; H.R. 1499, Protecting Consumer Access to Generic Drugs Act of 2019; S. 657, A bill to amend title XXVII of the Public Health Service Act to establish requirements with respect to prescription drug benefits; S. 709, Prescription Drug Pricing Dashboard Act; S. 977, Transparent Drug Pricing Act of 2019; S. 1895, Lower Health Care Costs Act; H.R. 2296, FAIR Drug Pricing Act of 2019; H.R. 3947, the Competition Prescription Act of 2019; H.R. 2279, the Safe Step Act; H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act; S. 2543, the Prescription Drug Pricing Reduction Act of 2019; H.R. 19 / S. 3129, the Lower Costs, More Cures Act of 2019
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANNE CASSITY | — |
| PHILLIP ADAM HARBISON | — |
| RONNA HAUSER | — |
| KARRY LA VIOLETTE | — |
| KALA SHANKLE | — |
| REEMA TANEJA | — |
Medicare/Medicaid MMM
H.R. 803 / S. 988, Improving Transparency and Accuracy in Medicare Part D Drug Spending Act; H.R. 1034 / S. 640, Phair Pricing Act of 2019; H.R. 1035, Prescription Drug Price Transparency Act, S. 475, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act, S. 476, Reducing Existing Costs Associated with Pharmaceuticals for Seniors (RxCAP) Act; H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs; H.R.448 / S. 99, Medicare Drug Price Negotiation Act; H.R. 275, Medicare Prescription Drug Price Negotiation Act of 2019; H.R. 1346, Medicare Buy-In and Health Care Stabilization Act of 2019; H.R. 366, Insulin Access for All Act of 2019; S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019; S. 205 / H.R. 937, Right Rebate Act of 2019; H.R. 1046 / S. 377, Medicare Negotiation and Competitive Licensing Act of 2019; H.R. 1781 / S. 801, the Payment Commission Data Act of 2019; H.R. 2113, Prescription Drug Sunshine, Transparency, Accountability and Reporting (STAR) Act of 2019; H.R. 2115, To amend title XI of the Social Security Act to provide greater transparency of discounts provided by drug manufacturers; Proposed rule, "Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Expenses, CMS-4180-P"; Proposed rule, "Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees, OIG-0936-P"; Proposed rule, Medicaid Program; Medicaid and Childrens Health Insurance Plan (CHIP) Managed Care - CMS-2408-P; H.R. 1323, Rural Hospital Frontier Fairness Act; S. 551, REFUND Act of 2019; S. 691, Medicare Extra Rx HELP Act of 2019; S. 773, Telehealth Innovation and Improvement Act of 2019; S. 814, Expanding Access to Diabetes Self-Management Training Act of 2019; H.R. 1384 / S. 1129, Medicare for All Act of 2019; H.R. 3417, The Beneficiary Education Tools, Telehealth, and Extenders Reauthorization Act of 2019; H.R. 3408, Shop Rx Act of 2019; S. 1384, Prescription Drug Rebate Reform Act of 2019; H.R. 2113, Prescription Drug STAR Act; H.R. 2115, Public Disclosure of Drug Discounts Act S. 2447, the Phair Relief Act; S. 2771, the Protecting Home Oxygen and Medical Equipment Act of 2019; S. 1861 / H.R. 3924, the Streamlining Part D Appeals Process Act; H.R. 4946, the Ensuring Seniors Access to Local Pharmacies Act of 2019; H.R. 5281, the Drug Price Transparency in Medicaid Act of 2019; H.R. 5442, the Lowest Price for Patients Act; Report language for H.R.1865, the Further Consolidated Appropriations Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANNE CASSITY | — |
| PHILLIP ADAM HARBISON | — |
| RONNA HAUSER | — |
| KARRY LA VIOLETTE | — |
| KALA SHANKLE | — |
| REEMA TANEJA | — |
Labor Issues/Antitrust/Workplace LBR
Final rule, "Defining and Delimiting the Exemptions for Executive, Administrative, Professional, Outside Sales and Computer Employees"
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANNE CASSITY | — |
| PHILLIP ADAM HARBISON | — |
| RONNA HAUSER | — |
| KARRY LA VIOLETTE | — |
| KALA SHANKLE | — |
| REEMA TANEJA | — |
Pharmacy PHA
H.R. 1959, Preserving Patient Access to Compounded Medications Act of 2019; H.R. 2376 / S. 1227, Prescription Pricing for the People Act of 2019; H.R. 3223 / S. 1532, Pharmacy Benefit Manager Accountability Study Act of 2019; H.R. 5198, the Patients' Right to Know Their Medication Act of 2019; H.R. 5304, the PBM Transparency in Prescription Drug Costs Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANNE CASSITY | — |
| PHILLIP ADAM HARBISON | — |
| RONNA HAUSER | — |
| KARRY LA VIOLETTE | — |
| KALA SHANKLE | — |
| REEMA TANEJA | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.